PD
ACAD icon

Point72 (DIFC)’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 (DIFC)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,764
Closed -$211K – 1121
2025
Q2 		$211K Buy
9,764
+5,539
+131% +$103K 0.01% 773
2025
Q1 		$70.2K Sell
4,225
-39,370
-90% -$715K ﹤0.01% 1145
2024
Q4 		$800K Buy
+43,595
New +$704K 0.03% 523
2024
Q3 		– Sell
-1,232
Closed -$20K – 1398
2024
Q2 		$20K Sell
1,232
-76,131
-98% -$1.23M ﹤0.01% 1233
2024
Q1 		$1.43M Buy
+77,363
New +$1.92M 0.05% 476

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Point72 (DIFC)'s ACAD Position: Q3 2025 in Review

Point72 (DIFC) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 9,764 shares — an estimated $211K sold.

Point72 (DIFC) first reported a position in ACAD in Q1 2024 and held it in 5 quarters. The position peaked at $1.43M in Q1 2024. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Point72 (DIFC) reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 9,764 Acadia Pharmaceuticals shares in Q3 2025, an estimated $211K.
  • Point72 (DIFC) first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Point72 (DIFC)'s Acadia Pharmaceuticals position peaked at $1.43M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.